Literature DB >> 2430188

Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons.

G H Wong, D V Goeddel.   

Abstract

Tumour necrosis factor (TNF) and lymphotoxin were initially described as tumoricidal proteins that are produced by activated macrophages and lymphocytes, respectively. Since TNF and lymphotoxin are structurally related, bind to the same cell surface receptor and have indistinguishable biological activities, they have been designated as TNF-alpha and TNF-beta, respectively. The multiple activities of these molecules indicate their importance in immunoregulative responses. Here we report that both TNF-alpha and TNF-beta have antiviral activity and synergize with interferons (IFNs) in the induction of resistance to both RNA and DNA virus infection in diverse cell types. These effects of TNFs are not due to the induction of IFN synthesis. Virus-infected cells are selectively killed by TNFs and this activity is accelerated by IFN-gamma. The production of TNFs is induced by viruses, further suggesting the importance of TNFs in the physiological antiviral response.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2430188     DOI: 10.1038/323819a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  194 in total

1.  A cis-acting element in the 3'-untranslated region of human TNF-alpha mRNA renders splicing dependent on the activation of protein kinase PKR.

Authors:  F Osman; N Jarrous; Y Ben-Asouli; R Kaempfer
Journal:  Genes Dev       Date:  1999-12-15       Impact factor: 11.361

2.  Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells.

Authors:  Anne-Sophie Beignon; Jean-Paul Briand; Sylviane Muller; Charalambos D Partidos
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

3.  Robust expression of TNF-alpha, IL-1beta, RANTES, and IP-10 by human microglial cells during nonproductive infection with herpes simplex virus.

Authors:  J R Lokensgard; S Hu; W Sheng; M vanOijen; D Cox; M C Cheeran; P K Peterson
Journal:  J Neurovirol       Date:  2001-06       Impact factor: 2.643

4.  Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors.

Authors:  K B Elkon; C C Liu; J G Gall; J Trevejo; M W Marino; K A Abrahamsen; X Song; J L Zhou; L J Old; R G Crystal; E Falck-Pedersen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

5.  Critical role of the C-terminus in the biological activities of human tumour necrosis factor-alpha.

Authors:  K Gase; V G Korobko; H G Wisniewski; J Le; V N Dobrynin; S A Filippov; W Gutsche; Y N Maksimova; B Schlott; L N Shingarova
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

6.  Inhibition of Rickettsia conorii growth by recombinant tumor necrosis factor alpha: enhancement of inhibition by gamma interferon.

Authors:  E Manor; I Sarov
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

7.  Beta interferon subtype 1 induction by tumor necrosis factor.

Authors:  H Jacobsen; J Mestan; S Mittnacht; C W Dieffenbach
Journal:  Mol Cell Biol       Date:  1989-07       Impact factor: 4.272

8.  Hepatic expression of tumour necrosis factor-alpha in chronic hepatitis B virus infection.

Authors:  M J Hussain; J Y Lau; R Williams; D Vergani
Journal:  J Clin Pathol       Date:  1994-12       Impact factor: 3.411

9.  Enhancement of human immunodeficiency virus production by natural lymphotoxin.

Authors:  T Matsuyama; Y Hamamoto; S Kobayashi; M Kurimoto; J Minowada; N Kobayashi; N Yamamoto
Journal:  Med Microbiol Immunol       Date:  1988       Impact factor: 3.402

10.  Protective effect of exogenous recombinant mouse interferon-gamma and tumour necrosis factor-alpha on ectromelia virus infection in susceptible BALB/c mice.

Authors:  A V Atrasheuskaya; E K Bukin; T M Fredeking; G M Ignatyev
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.